In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lonza acquires UCB-Bioproducts, UCB's manufacturing arm

Executive Summary

Swiss specialty chemicals company Lonza has acquired UCB-Bioproducts, the peptide-drug-manufacturing business of Belgian pharmaceutical company UCB. The deal builds on a long-term supply agreement established last May between the two, under which Lonza is manufacturing PEGylated antibody-fragment-based bulk actives for UCB.
Deal Industry
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Full Acquisition

Related Companies